文献速递心脑血管急症复苏、休克与脓毒症重症综合管理与镇静镇痛

体外生命支持用于梗死相关心源性休克

Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
PubMed 文献 · N Engl J Med · 2023-08-26
一句话结论急性心梗合并心源性休克且计划早期血运重建者,早期ECLS较单纯药物治疗未降低30天全因死亡风险(47.8% vs 49.0%,RR 0.98,95%CI 0.80–1.19)。

ECLS-SHOCK多中心随机试验纳入急性心肌梗死合并心源性休克、计划早期血运重建的患者,随机接受早期ECLS+常规药物治疗(ECLS组)或单纯常规药物治疗(对照组)。30天全因死亡ECLS组47.8%(100/209)vs 对照组49.0%(102/208),相对风险0.98(95%CI 0.80–1.19;P=0.81)。ECLS组中重度出血23.4% vs 9.6%(RR 2.44;95%CI 1.50–3.95),需干预的外周血管并发症11.0% vs 3.8%(RR 2.86;95%CI 1.31–6.25)。研究提示在该人群中早期ECLS未降低30天死亡风险,且出血与血管并发症增加。

要点

  • 急性心梗合并心源性休克并计划早期血运重建者,30天全因死亡ECLS组47.8% vs 对照组49.0%(RR 0.98;95%CI 0.80–1.19;P=0.81),未降低死亡风险。
  • ECLS组中重度出血23.4% vs 对照组9.6%,相对风险2.44(95%CI 1.50–3.95)。
  • ECLS组需干预的外周血管并发症11.0% vs 对照组3.8%,相对风险2.86(95%CI 1.31–6.25)。
  • 机械通气中位时间ECLS组7天(IQR 4–12)vs 对照组5天(IQR 3–9),中位差值1天(95%CI 0–2)。
  • 共420例随机、417例纳入最终分析,多中心试验(ECLS-SHOCK,NCT03637205)。

适用人群与场景

  • 急性心肌梗死合并心源性休克、计划早期血运重建的患者。

处置流程与药物剂量

  • 早期ECLS加常规药物治疗(ECLS组)或单纯常规药物治疗(对照组),两组均计划早期血运重建。

研究设计与关键结果

  • 多中心随机试验,420例随机、417例纳入最终分析;早期ECLS+常规药物治疗(ECLS组)vs 单纯常规药物治疗(对照组)。
  • 主要终点30天全因死亡:ECLS组100/209例(47.8%)vs 对照组102/208例(49.0%),相对风险0.98(95%CI 0.80–1.19;P=0.81)。
  • 机械通气中位时间:ECLS组7天(IQR 4–12)vs 对照组5天(IQR 3–9),中位差值1天(95%CI 0–2)。
  • 中重度出血:ECLS组23.4% vs 对照组9.6%,相对风险2.44(95%CI 1.50–3.95)。
  • 需干预的外周血管并发症:ECLS组11.0% vs 对照组3.8%,相对风险2.86(95%CI 1.31–6.25)。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(ECLS-SHOCK,NCT03637205)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对急性心梗合并心源性休克且计划早期血运重建的患者,早期ECLS未降低30天全因死亡风险,且中重度出血(23.4% vs 9.6%)与需干预的外周血管并发症(11.0% vs 3.8%)增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extracorporeal life support (ECLS) is increasingly used in the treatment of infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality.

METHODS: In this multicenter trial, patients with acute myocardial infarction complicated by cardiogenic shock for whom early revascularization was planned were randomly assigned to receive early ECLS plus usual medical treatment (ECLS group) or usual medical treatment alone (control group). The primary outcome was death from any cause at 30 days. Safety outcomes included bleeding, stroke, and peripheral vascular complications warranting interventional or surgical therapy.

RESULTS: A total of 420 patients underwent randomization, and 417 patients were included in final analyses. At 30 days, death from any cause had occurred in 100 of 209 patients (47.8%) in the ECLS group and in 102 of 208 patients (49.0%) in the control group (relative risk, 0.98; 95% confidence interval [CI], 0.80 to 1.19; P = 0.81). The median duration of mechanical ventilation was 7 days (interquartile range, 4 to 12) in the ECLS group and 5 days (interquartile range, 3 to 9) in the control group (median difference, 1 day; 95% CI, 0 to 2). The safety outcome consisting of moderate or severe bleeding occurred in 23.4% of the patients in the ECLS group and in 9.6% of those in the control group (relative risk, 2.44; 95% CI, 1.50 to 3.95); peripheral vascular complications warranting intervention occurred in 11.0% and 3.8%, respectively (relative risk, 2.86; 95% CI, 1.31 to 6.25).

CONCLUSIONS: In patients with acute myocardial infarction complicated by cardiogenic shock with planned early revascularization, the risk of death from any cause at the 30-day follow-up was not lower among the patients who received ECLS therapy than among those who received medical therapy alone. (Funded by the Else Kröner Fresenius Foundation and others; ECLS-SHOCK ClinicalTrials.gov number, NCT03637205.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Thiele H, Zeymer U, Akin I, et al. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N Engl J Med. 2023. PMID: 37634145. doi:10.1056/NEJMoa2307227

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。